醫學化學通訊歡迎在藥物化學和相關藥物發現科學方面的重要研究和評論文章。我們接受通訊和全紙風格的文章。在醫學化學通訊上發表的研究論文必須比以前發表的論文有顯著的進步，或者帶來新的想法或結果，這些想法或結果可能會對他們的領域產生強大的影響。期刊范圍內的領域包括：新型化學或生化實體的設計、合成和生物評價。為了適合發表，這些必須表現出顯著的潛力，作為新的藥物制劑，工具，探針或潛在的藥物。對已知化學或生物化學實體的修改，可使對它們的結構-活性關系有更大的了解，改善它們的性質或提供其他有重要價值的信息，例如，為已知的試劑確定新目標。常規的修改很少或沒有改進，不適合醫學通訊。注意，只有在明確的陽性對照和陰性對照的情況下進行新化合物或現有化合物作為藥理學試劑進行測試的研究，并在原稿中參考現有最有效的藥劑，才會考慮這些研究。這種類型的研究應該包括一個明確定義和假設驅動的復合設計理論。潛在的抗菌藥物應進行細胞毒性和對非相關病原體的活性測試。在更廣泛的化學和生物科學(例如，使合成化學，化學生物學，組學科學，結構生物學，納米科學)的新方法和技術應用于藥物發現。計算研究是受歡迎的，因為它們大大提高了藥物化學知識。使用已建立的計算方法進行的研究應包括原始預測，并應附以新的實驗數據，以驗證所作的預測。報道新的計算方法的研究必須通過與實驗數據的比較來證明其在藥物化學中的應用。不清楚地將所得結果與實驗數據聯系起來的計算研究，或者沒有顯示出實用價值的計算研究(或者實用價值不太可能顯著促進該領域的發展)，不適合醫學化學通訊。請注意，沒有實驗數據的對接研究不適合發表在雜志上。研究化合物的分子結構對藥物動力學行為和藥效學的影響。請注意，只專注于藥物傳遞劑的研究不適合在醫學化學通訊發表。為了幫助編輯和審稿人評估每一篇投稿的重要性，我們要求所有投稿作者在投稿時提供一份簡要的重要性陳述。這應該包括一句話來總結手稿中最重要的發現，第二句話來說明為什么這是該領域的重大進展。這一重要性聲明應具體側重于所提交研究報告的重要性，而不是該領域的重要性。

MedChemComm welcomes significant research and review articles in medicinal chemistry and related drug discovery science. We accept both communication and full paper style articles.Research articles published in MedChemComm must show a significant advance on previously published work, or bring new thinking or results which will potentially have a strong impact in their field.Examples of areas within the journal's scope are:Design, synthesis and biological evaluation of novel chemical or biochemical entities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.Modifications of known chemical or biochemical entities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or which provide other information of significant value, for example, the identification of a new target for a known agent. Routine modifications with minimal or no improvement are not suitable for MedChemComm.Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls and reference is made in the manuscript to the most powerful existing agents. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, structural biology, nanoscience) with application to drug discovery.Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies which report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or which has no demonstrated utility (or where the utility is unlikely to significantly advance the field) is not suitable for MedChemComm. Please note that docking studies presented without experimental data are not suitable for publication in the journal.Studies which examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.Note that studies which focus solely on drug delivery agents are not suitable for publication in MedChemComm.To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.